{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:44:58Z","timestamp":1793263498317,"version":"4.5.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,27]],"date-time":"2023-12-27T00:00:00Z","timestamp":1703635200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.jaci.2023.12.013","type":"journal-article","created":{"date-parts":[[2023,12,26]],"date-time":"2023-12-26T21:30:45Z","timestamp":1703626245000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A\u00a0clinical review"],"prefix":"10.1016","volume":"154","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Boguniewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuo","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doral","family":"Fredericks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Rubenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly A.","family":"McHale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2023.12.013_bib2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2014.04.019","article-title":"Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions","volume":"40","author":"Di Meglio","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.12.013_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1146\/annurev-immunol-032713-120245","article-title":"The aryl hydrocarbon receptor: multitasking in the immune system","volume":"32","author":"Stockinger","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jaci.2023.12.013_bib4","first-page":"891","article-title":"Immuno-pathogenesis of chronic inflammatory skin diseases: novel molecular targets and biomarkers","volume":"12","author":"Raimondo","year":"2022","journal-title":"Life (Basel)"},{"key":"10.1016\/j.jaci.2023.12.013_bib5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor\u2013modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdermsci.2015.07.011","article-title":"Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor","volume":"80","author":"Furue","year":"2015","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib7","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.it.2009.06.005","article-title":"The aryl hydrocarbon receptor in immunity","volume":"30","author":"Esser","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jaci.2023.12.013_bib9","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/cpdd.439","article-title":"Systemic pharmacokinetics, safety, and preliminary efficacy of topical AhR agonist tapinarof: results of a phase 1 study","volume":"7","author":"Bissonnette","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jaci.2023.12.013_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jaad.2018.06.047","article-title":"A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis","volume":"80","author":"Peppers","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaci.2023.12.013_bib12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial","volume":"87","author":"Strober","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib13","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jaci.2023.12.013_bib14","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaip.2019.01.005","article-title":"Atopic dermatitis in US adults: from population to health care utilization","volume":"7","author":"Silverberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.12.013_bib15","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-019-00453-7","article-title":"Adult-onset atopic dermatitis: characteristics and management","volume":"20","author":"Vakharia","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib16","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1067\/mjd.2000.107773","article-title":"The prevalence of atopic dermatitis in Oregon schoolchildren","volume":"43","author":"Laughter","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1390","article-title":"Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics","volume":"11","author":"Kwatra","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.jaci.2023.12.013_bib18","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/jid.2014.70","article-title":"Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study","volume":"134","author":"Halvorsen","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.anai.2019.07.008","article-title":"A real-world study evaluating adequacy of existing systemic treatments for patients with moderate-to-severe atopic dermatitis (QUEST-AD): baseline treatment patterns and unmet needs assessment","volume":"123","author":"Wei","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.12.013_bib20","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.12.013_bib21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2023.12.013_bib22","first-page":"345","volume":"396","author":"Langan","year":"2020","journal-title":"Atopic dermatitis Lancet"},{"key":"10.1016\/j.jaci.2023.12.013_bib23","first-page":"1","article-title":"The impact of air pollution on atopic dermatitis","author":"Lai","year":"2023","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaci.2023.12.013_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaci.2023.12.013_bib25","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaci.2023.12.013_bib26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3390\/antiox9030196","article-title":"Oxidative stress and atopic dermatitis","volume":"9","author":"Bertino","year":"2020","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jaci.2023.12.013_bib27","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.3390\/ijms21176206","article-title":"Oxidative stress as an important contributor to the pathogenesis of psoriasis","volume":"21","author":"Ple\u0144kowska","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib28","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/jid.2008.29","article-title":"Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum","volume":"128","author":"Kezic","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2022.100131","article-title":"Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis","volume":"2","author":"Beck","year":"2022","journal-title":"JID Innov"},{"key":"10.1016\/j.jaci.2023.12.013_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910841","article-title":"Skin barrier dysregulation in psoriasis","volume":"22","author":"Orsmond","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.875492","article-title":"Unmet medical needs in chronic, non-communicable inflammatory skin diseases","volume":"9","author":"Ujiie","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.jaci.2023.12.013_bib32","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000484407","article-title":"Emerging treatment options in atopic dermatitis: topical therapies","volume":"233","author":"Nygaard","year":"2018","journal-title":"Dermatology"},{"key":"10.1016\/j.jaci.2023.12.013_bib33","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.3390\/jcm11174974","article-title":"New and upcoming topical treatments for atopic dermatitis: a review of the literature","volume":"11","author":"Sideris","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jaci.2023.12.013_bib34","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jdv.18925","article-title":"Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research","volume":"37","author":"Bissonnette","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaci.2023.12.013_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/pr.114.009001","article-title":"The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology","volume":"67","author":"Esser","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jaci.2023.12.013_bib36","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1038\/s41467-022-34773-w","article-title":"Cryo-EM structure of the agonist-bound Hsp90-XAP2-AHR cytosolic complex","volume":"13","author":"Gruszczyk","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jaci.2023.12.013_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cotox.2017.01.001","article-title":"Canonical and non-canonical aryl hydrocarbon receptor signaling pathways","volume":"2","author":"Wright","year":"2017","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.jaci.2023.12.013_bib38","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cotox.2017.01.006","article-title":"And now for something completely different: diversity in ligand-dependent activation of Ah receptor responses","volume":"2","author":"Denison","year":"2017","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.jaci.2023.12.013_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.624293","article-title":"The aryl hydrocarbon receptor as a modulator of anti-viral immunity","volume":"12","author":"Torti","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.12.013_bib40","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/biomedicines10051087","article-title":"Aryl hydrocarbon receptors: evidence of therapeutic targets in chronic inflammatory skin diseases","volume":"10","author":"Kim","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaci.2023.12.013_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19123882","article-title":"The aryl hydrocarbon receptor and the maintenance of lung health","volume":"19","author":"Guerrina","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bbagen.2010.11.007","article-title":"FRET analysis of protein tyrosine kinase c-Src activation mediated via aryl hydrocarbon receptor","volume":"1810","author":"Dong","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jaci.2023.12.013_bib43","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.3390\/ijms21176404","article-title":"Epigenetic regulations\u00a0of AhR in the aspect of immunomodulation","volume":"21","author":"Wajda","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2017.12.012","article-title":"Regulation of the immune response by the aryl hydrocarbon receptor","volume":"48","author":"Guti\u00e9rrez-V\u00e1zquez","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.12.013_bib45","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.3390\/ijms19123851","article-title":"The role of the aryl hydrocarbon receptor (AHR) in immune and inflammatory diseases","volume":"19","author":"Neavin","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030336","article-title":"Pharmaceutically active microbial AhR agonists as innovative biodrugs in inflammation","volume":"15","author":"Puccetti","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jaci.2023.12.013_bib47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41577-019-0125-8","article-title":"The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease","volume":"19","author":"Rothhammer","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jaci.2023.12.013_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1057555","article-title":"Aryl hydrocarbon receptor: the master regulator of immune responses in allergic diseases","volume":"13","author":"Riaz","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaci.2023.12.013_bib49","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3390\/cells10113176","article-title":"Role of AHR ligands in skin homeostasis and cutaneous inflammation","volume":"10","author":"Fern\u00e1ndez-Gallego","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jaci.2023.12.013_bib50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1084\/jem.20160789","article-title":"The aryl hydrocarbon receptor controls cell-fate decisions in B cells","volume":"214","author":"Vaidyanathan","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.12.013_bib51","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.cotox.2017.01.009","article-title":"Dioxin and the AH receptor: synergy of discovery","volume":"2","author":"Birnbaum","year":"2017","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.jaci.2023.12.013_bib52","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.3390\/ijms20215424","article-title":"Aryl hydrocarbon receptor in atopic dermatitis and psoriasis","volume":"20","author":"Furue","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib53","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/imm.12046","article-title":"The aryl hydrocarbon receptor: a molecular pathway for the environmental control of the immune response","volume":"138","author":"Quintana","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.jaci.2023.12.013_bib54","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1124\/pr.113.007823","article-title":"Aryl hydrocarbon receptor control of adaptive immunity","volume":"65","author":"Quintana","year":"2013","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.jaci.2023.12.013_bib55","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1084\/jem.20081438","article-title":"Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells","volume":"206","author":"Veldhoen","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaci.2023.12.013_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111963","article-title":"The aryl hydrocarbon receptor cell intrinsically promotes resident memory CD8+ T cell differentiation and function","volume":"42","author":"Dean","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.jaci.2023.12.013_bib57","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jid.2023.03.1662","article-title":"Ligand activation of the aryl hydrocarbon receptor upregulates epidermal uridine diphosphate glucose ceramide glucosyltransferase and glucosylceramides","volume":"143","author":"Sutter","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib58","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cotox.2017.02.003","article-title":"Diversity as opportunity: insights from 600 million years of AHR evolution","volume":"2","author":"Hahn","year":"2017","journal-title":"Curr Opin Toxicol"},{"key":"10.1016\/j.jaci.2023.12.013_bib59","doi-asserted-by":"crossref","first-page":"8851","DOI":"10.1073\/pnas.0701764104","article-title":"Lightening up the UV response by identification of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation","volume":"104","author":"Fritsche","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib60","doi-asserted-by":"crossref","first-page":"15422","DOI":"10.1016\/S0021-9258(18)47743-5","article-title":"Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances","volume":"262","author":"Rannug","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jaci.2023.12.013_bib61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3390\/nu9030223","article-title":"Antioxidants for healthy skin: the emerging role of aryl hydrocarbon receptors and nuclear factor-erythroid 2-related factor-2","volume":"9","author":"Furue","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.jaci.2023.12.013_bib62","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1038\/jid.2013.92","article-title":"Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin","volume":"133","author":"Magiatis","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib63","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.jid.2020.03.605","article-title":"Differential ligand binding distinguishes therapeutic from pathologic aryl hydrocarbon receptor (AhR) modulating agents: implications for inflammatory skin disease","volume":"140","author":"Smith","year":"2020","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47138-z","article-title":"Modeling the binding of diverse ligands within the Ah receptor ligand binding domain","volume":"9","author":"Giani Tagliabue","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jaci.2023.12.013_bib65","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00281-013-0394-4","article-title":"Functions of the aryl hydrocarbon receptor in the skin","volume":"35","author":"Esser","year":"2013","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jaci.2023.12.013_bib66","unstructured":"Dermavant data on file (DMVT-505 Th2 polarization [Study report no. 2015N230011_01];Apr 2015)."},{"key":"10.1016\/j.jaci.2023.12.013_bib67","unstructured":"Dermavant data on file (DMVT-505 AD mouse model [study report no. 2016N300192]; Oct 2016)."},{"key":"10.1016\/j.jaci.2023.12.013_bib68","first-page":"917","article-title":"Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis","volume":"123","author":"van den Bogaard","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2023.12.013_bib70","article-title":"Tapinarof inhibits the formation, cytokine production, and persistence of resident memory T cells in\u00a0vitro. Poster presented at Winter Clinical Dermatology Conference","volume":"13-18","author":"Mooney","year":"2023","journal-title":"January"},{"key":"10.1016\/j.jaci.2023.12.013_bib71","unstructured":"Silverberg JI, et\u00a0al. Presentation at the Congress of the European Academy of Dermatology and Venereology, Berlin, Germany, October 11-14, 2023."},{"key":"10.1016\/j.jaci.2023.12.013_bib72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.10.037","article-title":"Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis","volume":"80","author":"Robbins","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib73","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2020.04.181","article-title":"A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: secondary efficacy and patient-reported outcomes","volume":"84","author":"Stein Gold","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaci.2023.12.013_bib74","article-title":"Maximal use study of tapinarof cream 1% in subjects with extensive plaque psoriasis","volume":"4","author":"Jett","year":"2020","journal-title":"SKIN - J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2023.12.013_bib75","doi-asserted-by":"crossref","unstructured":"Paller A, Jett JE, Hebert AA, Brown PM, Butners V, Fitzgerald N, et\u00a0al. Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children: outcomes from the 4-week maximal usage trial. Presentation at the 5th Annual Revolutionizing Atopic Dermatitis (RAD) Conference, April 29-May 1, 2023;Washington, DC, USA.","DOI":"10.1093\/bjd\/ljad162.028"},{"key":"10.1016\/j.jaci.2023.12.013_bib76","doi-asserted-by":"crossref","unstructured":"Stein Gold L, Brown P, Rubenstein D, Tabolt G, Jett J, SC P. Tapinarof cream 1% once daily for plaque psoriasis in two pivotal phase 3 trials: minimal systemic exposure is consistent with adverse event profile. Poster presented at the American Academy of Dermatology Annual Meeting; March 17-21, 2023;New Orleans, LA.","DOI":"10.1016\/j.jaad.2023.07.916"},{"key":"10.1016\/j.jaci.2023.12.013_bib77","doi-asserted-by":"crossref","first-page":"s50","DOI":"10.25251\/skin.6.supp.50","article-title":"Exposure-response analysis demonstrates response to tapinarof is driven by local effects at sites of application","volume":"6","author":"Del Rosso","year":"2022","journal-title":"SKIN \u2013 J Cutan Med Surg"},{"key":"10.1016\/j.jaci.2023.12.013_bib78","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.3390\/ijms21228797","article-title":"The aryl hydrocarbon receptor in asthma: friend or foe?","volume":"21","author":"Poulain-Godefroy","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib79","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.anai.2017.10.037","article-title":"The atopic march: critical evidence and clinical relevance","volume":"120","author":"Hill","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2023.12.013_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108603","article-title":"Acteoside exerts immunomodulatory effects on dendritic cells via aryl hydrocarbon receptor activation and ameliorates Th2-mediated allergic asthma\u00a0by inducing Foxp3+ regulatory T cells","volume":"106","author":"Chang","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaci.2023.12.013_bib81","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002350R","article-title":"Aryl hydrocarbon receptor deficiency causes the development of chronic obstructive pulmonary disease through the integration of multiple pathogenic mechanisms","volume":"35","author":"Guerrina","year":"2021","journal-title":"FASEB J"},{"key":"10.1016\/j.jaci.2023.12.013_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.labinv.2022.100012","article-title":"Aryl hydrocarbon receptor activation coordinates mouse small intestinal epithelial cell programming","volume":"103","author":"Zhou","year":"2023","journal-title":"Lab Invest"},{"key":"10.1016\/j.jaci.2023.12.013_bib83","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.immuni.2018.07.010","article-title":"The environmental sensor AHR protects from inflammatory damage by maintaining intestinal stem cell homeostasis and barrier integrity","volume":"49","author":"Metidji","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.jaci.2023.12.013_bib84","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/mi.2016.133","article-title":"Tryptophan metabolite activation of the aryl hydrocarbon receptor regulates IL-10 receptor expression on intestinal epithelia","volume":"10","author":"Lanis","year":"2017","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jaci.2023.12.013_bib85","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/ibd\/izy126","article-title":"Anti-TNF therapy induces CD4+ T-cell production of IL-22 and promotes epithelial repairs in patients with Crohn\u2019s disease","volume":"24","author":"Fang","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jaci.2023.12.013_bib86","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cyto.2014.09.007","article-title":"IL-22, cell regeneration and autoimmunity","volume":"74","author":"Nikoopour","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.jaci.2023.12.013_bib87","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/icb.2014.2","article-title":"Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis","volume":"92","author":"Fukumoto","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.jaci.2023.12.013_bib88","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/ecco-jcc\/jjw010","article-title":"MicroRNA-124 promotes intestinal inflammation by targeting aryl hydrocarbon receptor in Crohn\u2019s disease","volume":"10","author":"Zhao","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.jaci.2023.12.013_bib89","article-title":"The aryl hydrocarbon receptor instructs the immunomodulatory profile of a subset of Clec4a4(+) eosinophils unique to the small intestine","volume":"119","author":"Wang","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib90","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.gastro.2017.06.065","article-title":"Pathophysiology of eosinophilic esophagitis","volume":"154","author":"O'Shea","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaci.2023.12.013_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/ftox.2022.791082","article-title":"More than meets the eye: the aryl hydrocarbon receptor is an environmental sensor, physiological regulator and a therapeutic target in ocular disease","volume":"4","author":"Hammond","year":"2022","journal-title":"Front Toxicol"},{"key":"10.1016\/j.jaci.2023.12.013_bib92","doi-asserted-by":"crossref","first-page":"10442","DOI":"10.1073\/pnas.190256997","article-title":"Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice","volume":"97","author":"Lahvis","year":"2000","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053520","article-title":"Oculomotor deficits in aryl hydrocarbon receptor null mouse","volume":"8","author":"Chevallier","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.jaci.2023.12.013_bib94","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/hmg\/ddy165","article-title":"A splicing mutation in aryl hydrocarbon receptor associated with retinitis pigmentosa","volume":"27","author":"Zhou","year":"2018","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.jaci.2023.12.013_bib95","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1164\/rccm.200503-468OC","article-title":"A novel low molecular weight inhibitor of dendritic cells and B cells blocks allergic inflammation","volume":"173","author":"Ettmayer","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaci.2023.12.013_bib96","first-page":"1158","article-title":"Activation of the aryl hydrocarbon receptor is essential for mediating the anti-inflammatory effects of a novel low-molecular-weight compound. Blood","volume":"112","author":"Lawrence","year":"2008","journal-title":"J Am Soc Hematol"},{"key":"10.1016\/j.jaci.2023.12.013_bib97","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.3390\/ijms22094335","article-title":"Aryl hydrocarbon receptor agonist VAF347 impedes retinal pathogenesis in diabetic mice","volume":"22","author":"Zapadka","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib98","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41586-018-0119-x","article-title":"Microglial control of astrocytes in response to microbial metabolites","volume":"557","author":"Rothhammer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.jaci.2023.12.013_bib99","doi-asserted-by":"crossref","first-page":"E6145","DOI":"10.1073\/pnas.1607843113","article-title":"Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor","volume":"113","author":"Kaye","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.jaci.2023.12.013_bib100","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00415-014-7264-4","article-title":"A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis","volume":"261","author":"Vollmer","year":"2014","journal-title":"J Neurol"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923025472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674923025472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T16:16:30Z","timestamp":1737389790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674923025472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0091674923025472"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2023.12.013","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tapinarof validates the aryl hydrocarbon receptor as a therapeutic target: A\u00a0clinical review","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2023.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}